Visceral & Metabolic

Definition

Visceral and Metabolic peptides specifically target visceral adiposity and deep metabolic dysfunction — primarily through mechanisms independent of appetite suppression. This category is distinct from Category 1 (GLP-axis) where weight loss is driven largely by appetite reduction: compounds here act on adipose tissue biology, hepatic lipid metabolism, or nicotinamide N-methyltransferase (NNMT) pathways. The clinical application is patients with metabolic syndrome, visceral obesity, or fatty liver disease who have not achieved sufficient visceral fat reduction with lifestyle or GLP-1 therapy alone.

Mechanism of Action

Tesamorelin (a GHRH analog also appearing in Category 5) is included here because its primary clinical application is visceral fat reduction through GH-driven lipolysis. By stimulating pulsatile GH release, Tesamorelin activates hormone-sensitive lipase in visceral adipocytes and promotes fatty acid oxidation. Its visceral selectivity compared to subcutaneous fat may relate to the higher density of GH receptors in omental and mesenteric adipose tissue. 5-Amino-1MQ is a small molecule (technically not a peptide but often categorized alongside peptide metabolic protocols) that inhibits nicotinamide N-methyltransferase (NNMT) — an enzyme that converts NAD+ precursors to N-methylnicotinamide. NNMT inhibition preserves cellular NAD+ pools, activates SIRT1 pathways, reduces lipid droplet formation in adipocytes, and in rodent models significantly reduces fat mass and improves metabolic parameters.

Regulatory Status

Tesamorelin (Egrifta, Theratechnologies) is FDA-approved specifically for HIV-associated lipodystrophy. Off-label use for visceral adiposity in non-HIV patients is investigational and not FDA-approved. 5-Amino-1MQ is not FDA-approved and is available primarily through research suppliers and some compounding pharmacies.

Evidence Base

Tesamorelin has Phase III RCT data in HIV-associated lipodystrophy showing 15–20% reduction in visceral adipose tissue as measured by CT scan. The mechanism translates logically to non-HIV metabolic patients, but formal RCT data in this population is limited. 5-Amino-1MQ has compelling rodent model data showing significant fat mass reduction, improved insulin sensitivity, and SIRT1 activation; human phase I safety and efficacy trials are underway but not yet published. The NNMT inhibition mechanism is genuinely novel and scientifically interesting.